Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A
IRWD
Get informed when a big investor buys or sells
+ FollowMarket Cap$712.77M
Close$
$12.27
183.3% upside
Current Fair Value
183.3% upsideUndervalued by 183.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $712.77 Million |
|---|---|
| Enterprise Value | $704.66 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.15 |
| Beta | 0.21 |
| Outstanding Shares | 163,451,000 |
Return
| Return on Equity | -2243.88% |
|---|---|
| Return on Assets | 55.92% |
| Return on Invested Capital | 102.67% |
Valuation & Multiples
| P/E Ratio | 6.81 |
|---|---|
| PEG | -2 |
| Price to Sales | 2.17 |
| Price to Book Ratio | -4.33 |
| Enterprise Value to Revenue | 1.95 |
| Enterprise Value to EBIT | 3.46 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | -19.61 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$92.11 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$0.26
Average shareholder expectationRevenue Estimate
$120.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0349▲ 3.24% |
|---|---|
| Total Calls | 11,474,820▲ 0.62% |
| Total Puts | 399,900▲ 1359.49% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.53%▲ 4.20% |
|---|---|
| Total Invested | $566.65M▲ 8.94% |
| Investors Holding | 234▲ 29.00% |
ESG Score
No data
About Ironwood Pharmaceuticals Inc
CEO: Mark Mallon